AMAG Pharmaceuticals, Inc. clinical trials

Acquired by Azurity Pharmaceuticals, Mar 14, 2025 · source ↗

The registry lists 24 studies whose lead sponsor is AMAG Pharmaceuticals, Inc.. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated May 22, 2026.

Studies

Recruiting first, then most recently updated. Showing 24 of 24. All Azurity Pharmaceuticals studies →

• A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)RecruitingNCT03619850Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric SubjectsRecruitingNCT03893045Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe PreeclampsiaTerminatedNCT03008616Phase 2/3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy AdultsTerminatedNCT04593784Phase 2

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)CompletedNCT00707876Phase 2

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney DiseaseCompletedNCT01052779Phase 2

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)CompletedNCT02694978Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm DeliveryCompletedNCT01004029Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm BirthCompletedNCT01146990

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal WomenCompletedNCT02940522Phase 1

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney DiseaseTerminatedNCT01264679Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney DiseaseTerminatedNCT01155388Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal WomenTerminatedNCT02937766Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• A Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency AnemiaCompletedNCT01114204Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on HemodialysisCompletedNCT01227616Phase 4

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency AnemiaCompletedNCT01114217Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency AnemiaCompletedNCT01114139Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and WomenCompletedNCT00360425Phase 1

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney DiseaseTerminatedNCT01155375Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis PatientsCompletedNCT00233597Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With ZofranCompletedNCT03973047Phase 1

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease PatientsCompletedNCT00255424Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease PatientsCompletedNCT00255437Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• A Crossover Safety Study of Ferumoxytol Versus PlaceboCompletedNCT00255450Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals